{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zerbo O"],"funding":["U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)"],"pagination":["894"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9974935"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(1)"],"pubmed_abstract":["We examined the effectiveness of maternal vaccination against SARS-CoV-2 infection in 30,311 infants born at Kaiser Permanente Northern California from December 15, 2020, to May 31, 2022. Using Cox regression, the effectiveness of ≥2 doses of COVID-19 vaccine received during pregnancy was 84% (95% confidence interval [CI]: 66, 93), 62% (CI: 39, 77) and 56% (CI: 34,71) during months 0-2, 0-4 and 0- 6 of a child's life, respectively, in the Delta variant period. In the Omicron variant period, the effectiveness of maternal vaccination in these three age intervals was 21% (CI: -21,48), 14% (CI: -9,32) and 13% (CI: -3,26), respectively. Over the entire study period, the incidence of hospitalization for COVID-19 was lower during the first 6 months of life among infants of vaccinated mothers comp"],"journal":["Nature communications"],"pubmed_title":["Maternal SARS-CoV-2 vaccination and infant protection against SARS-CoV-2 during the first six months of life."],"pmcid":["PMC9974935"],"funding_grant_id":["1R01AI168373-01"],"pubmed_authors":["Omer S","Ross P","Layefsky E","Klein NP","Ray GT","Fireman B","Goddard K","Lewis E","Zerbo O","Greenberg M"],"additional_accession":[]},"is_claimable":false,"name":"Maternal SARS-CoV-2 vaccination and infant protection against SARS-CoV-2 during the first six months of life.","description":"We examined the effectiveness of maternal vaccination against SARS-CoV-2 infection in 30,311 infants born at Kaiser Permanente Northern California from December 15, 2020, to May 31, 2022. Using Cox regression, the effectiveness of ≥2 doses of COVID-19 vaccine received during pregnancy was 84% (95% confidence interval [CI]: 66, 93), 62% (CI: 39, 77) and 56% (CI: 34,71) during months 0-2, 0-4 and 0- 6 of a child's life, respectively, in the Delta variant period. In the Omicron variant period, the effectiveness of maternal vaccination in these three age intervals was 21% (CI: -21,48), 14% (CI: -9,32) and 13% (CI: -3,26), respectively. Over the entire study period, the incidence of hospitalization for COVID-19 was lower during the first 6 months of life among infants of vaccinated mothers comp","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-05T13:01:27.087Z","creation":"2025-02-19T02:21:24.427Z"},"accession":"S-EPMC9974935","cross_references":{"pubmed":["36854660"],"doi":["10.1038/s41467-023-36547-4"]}}